Opportunity Information: Apply for RFA AG 14 003
Apply for RFA AG 14 003
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Collaborative Research Infrastructure to Develop Research Strategies to Identify Potential Therapeutic Targets Based on Genetic Factors Influencing Human Life Span and Health Span (U24)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866 Aging Research.
- This funding opportunity was created on Jul 18, 2013 and posted on Jul 18, 2013.
- Applicants must submit their applications by Nov 4, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $800,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $450,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Special district governments For profit organizations other than small businesses State governments County governments City or township governments Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Private institutions of higher education Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Institutes of Health (NIH) funding opportunity RFA-AG-14-003 supports a single U24 Cooperative Agreement to build and operate a collaborative research infrastructure focused on turning human genetics discoveries about life span and health span into practical, translational plans for therapeutic target identification. The core idea is not simply to generate more basic genetic associations, but to organize a coordinated, multidisciplinary effort that can take existing and emerging genetic findings related to longevity and healthy aging and systematically map them into credible intervention opportunities. In this announcement, a "target identification strategy" is defined in applied, translational terms: a deliberate set of research approaches aimed at a key step in developing new therapies or preventive interventions (or repurposing existing ones) to delay the onset of age-related conditions by identifying molecules, pathways, or biological activities that could be modified in a beneficial way.
Because this is a U24 cooperative agreement, NIH would expect substantial interaction with the awardee, including ongoing scientific coordination and shared responsibility for key decisions, rather than a hands-off grant relationship. The emphasis is on establishing a functioning infrastructure and team-based process that can evaluate genetic signals, prioritize them, and design research strategies that connect genetics to mechanism and then to actionable targets. This typically implies activities like developing frameworks for prioritizing candidate genes/variants/pathways, integrating multiple data types (for example, human genetic association signals with functional genomics, molecular pathway data, and disease/phenotype links), and planning validation approaches that move from statistical associations toward biological causality and druggability. The work is meant to support translational planning and strategy development, including identifying where interventions might modulate aging-related pathways and where there is credible opportunity for prevention, delay, or risk reduction across age-related diseases.
The scientific scope centers on genetic factors influencing human life span and health span, with health span understood in the practical sense of delaying or reducing the burden of age-related conditions rather than targeting a single disease in isolation. The infrastructure is meant to support a concerted strategy to translate genetic insights into intervention hypotheses, which can include either new therapeutic development paths or repurposing of existing agents. The announcement explicitly frames target identification as locating "molecules or pathways by which activities could be favorably modified," highlighting a preference for targets that are mechanistically interpretable and potentially modifiable by drugs, biologics, or other interventions. In practice, that means the team would be expected to address challenges such as distinguishing correlation from causation, understanding pleiotropy and tradeoffs, evaluating tissue- and cell-type specificity, and thinking through how genetic influences on longevity interact with known age-related disease biology.
In terms of administrative details, the opportunity is categorized as discretionary funding and uses the cooperative agreement mechanism. NIH anticipated making one award, with an estimated total funding amount of $800,000 and an award ceiling of $450,000. There was no cost sharing or matching requirement. The funding opportunity was posted on July 18, 2013, with an original and final application due date of November 4, 2013, and it was later archived on December 5, 2013. The CFDA number associated with the program is 93.866 (Aging Research), indicating alignment with NIH aging research priorities and, by extension, the National Institute on Aging as the likely lead institute.
Eligibility was broad across U.S.-based organizations and governmental entities, including public and private institutions of higher education, nonprofits (with and without 501(c)(3) status), for-profit organizations (other than small businesses were explicitly included alongside small businesses), and a wide range of state, local, and special district governments. The FOA also listed multiple institution types often highlighted in federal programs, such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, and other minority-serving institutions. Foreign institutions were not eligible to apply as primary applicants, but non-U.S. components of U.S. organizations were allowed, and foreign components as defined by NIH policy could be included, which signals openness to incorporating specialized expertise or resources internationally as part of a U.S.-led application.
Overall, RFA-AG-14-003 was designed to create a centralized, team-science capability that accelerates the translation of longevity and healthy aging genetics into well-justified therapeutic target strategies. Rather than funding a collection of independent projects, it aimed to fund a coordinated infrastructure with shared planning, prioritization, and translational decision-making, so that genetic discoveries could more reliably inform the next steps toward interventions that might extend health span and delay age-related disease onset. For reference and full requirements, NIH linked the complete announcement at http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-14-003.html, and provided NIH Office of Extramural Research web support contacts for access and technical linking issues.
Frequently Asked Questions (FAQs)
What is the funding opportunity RFA-AG-14-003?
RFA-AG-14-003 is a National Institutes of Health (NIH) funding opportunity that supported a single U24 Cooperative Agreement to build and operate a collaborative research infrastructure focused on translating human genetics discoveries about life span and health span into practical, translational plans for therapeutic target identification.
What is the main goal of this opportunity?
The main goal is to create a coordinated, multidisciplinary infrastructure and process that can take existing and emerging genetic findings related to longevity and healthy aging and systematically map them into credible intervention opportunities, with an emphasis on translational planning rather than generating additional basic genetic associations.
How does the FOA define a "target identification strategy"?
In this announcement, a "target identification strategy" is defined in applied, translational terms as a deliberate set of research approaches aimed at a key step in developing new therapies or preventive interventions (or repurposing existing ones) to delay the onset of age-related conditions, by identifying molecules, pathways, or biological activities that could be modified in a beneficial way.
What funding mechanism is used?
The opportunity uses the U24 Cooperative Agreement mechanism.
What does it mean that this is a U24 cooperative agreement?
Because it is a cooperative agreement, NIH expected substantial interaction with the awardee, including ongoing scientific coordination and shared responsibility for key decisions. This implies an active partnership model rather than a hands-off grant relationship.
How many awards did NIH anticipate making?
NIH anticipated making one award.
How much funding was available?
The estimated total funding amount was $800,000, and the award ceiling was $450,000.
Was cost sharing or matching required?
No. The opportunity stated there was no cost sharing or matching requirement.
What scientific area does this opportunity focus on?
The scientific scope centers on genetic factors influencing human life span and health span, with health span understood in a practical sense as delaying or reducing the burden of age-related conditions rather than focusing on a single disease in isolation.
Is the emphasis on discovering new genetic associations?
No. The core idea is not simply to generate more basic genetic associations, but to organize a coordinated effort that can translate genetic findings into credible intervention opportunities and therapeutic target identification plans.
What types of activities were implied by the infrastructure-building focus?
The announcement described activities typically implied by this work, such as developing frameworks for prioritizing candidate genes/variants/pathways, integrating multiple data types (for example, human genetic association signals with functional genomics, molecular pathway data, and disease/phenotype links), and planning validation approaches that move from statistical associations toward biological causality and druggability.
What does "translational planning" mean in this context?
Here, translational planning refers to strategy development that connects genetics to mechanism and then to actionable targets, including identifying where interventions might modulate aging-related pathways and where there is credible opportunity for prevention, delay, or risk reduction across age-related diseases.
What kinds of intervention paths were included?
The FOA contemplated intervention hypotheses that could include new therapeutic development paths or repurposing of existing agents.
What types of targets were preferred?
The announcement highlighted a preference for targets that are mechanistically interpretable and potentially modifiable by drugs, biologics, or other interventions, framing target identification as locating "molecules or pathways by which activities could be favorably modified."
What scientific challenges did the team need to account for?
The FOA noted challenges such as distinguishing correlation from causation, understanding pleiotropy and tradeoffs, evaluating tissue- and cell-type specificity, and considering how genetic influences on longevity interact with known age-related disease biology.
What is meant by health span in this announcement?
Health span is described in practical terms as delaying or reducing the burden of age-related conditions, rather than addressing a single disease in isolation.
What kind of overall structure was NIH trying to fund?
Rather than funding a collection of independent projects, NIH aimed to fund a centralized, coordinated infrastructure with shared planning, prioritization, and translational decision-making so genetic discoveries could more reliably inform next steps toward interventions that might extend health span and delay age-related disease onset.
What is the CFDA number associated with this program?
The CFDA number listed was 93.866 (Aging Research).
What does the CFDA number indicate about the program alignment?
The listing of CFDA 93.866 indicates alignment with NIH aging research priorities and suggests the National Institute on Aging as the likely lead institute.
When was the opportunity posted and when were applications due?
The opportunity was posted on July 18, 2013. The original and final application due date was November 4, 2013.
Is this funding opportunity still open?
No. It was later archived on December 5, 2013.
What type of funding category was this opportunity listed under?
It was categorized as discretionary funding.
Who was eligible to apply?
Eligibility was broad across U.S.-based organizations and governmental entities, including public and private institutions of higher education, nonprofits (with and without 501(c)(3) status), for-profit organizations (including small businesses and other-than-small businesses), and various state, local, and special district governments.
Were minority-serving institutions included in the eligibility list?
Yes. The FOA listed multiple institution types often highlighted in federal programs, including HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, and other minority-serving institutions.
Are foreign institutions eligible to apply as the primary applicant?
No. Foreign institutions were not eligible to apply as primary applicants.
Can a U.S. applicant include non-U.S. components or foreign components?
Yes. Non-U.S. components of U.S. organizations were allowed, and foreign components as defined by NIH policy could be included, indicating that international expertise or resources could be incorporated as part of a U.S.-led application.
Where can applicants find the full announcement?
NIH linked the complete announcement at http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-14-003.html.
Who was listed for technical support related to access or linking issues?
The opportunity referenced NIH Office of Extramural Research web support contacts for access and technical linking issues.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: BLM CA NEED San Joaquin River Gorge Hands on the Land Program
Previous opportunity: Adding Legacy Clinical Data to the Federal Interagency Traumatic Brain Injury (FITBIR) Informatics System (R03)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 14 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 14 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| American Indians into Nursing Apply for HHS 2013 IHS NU 0001 Funding Number: HHS 2013 IHS NU 0001 Agency: Indian Health Service Category: Health Funding Amount: $350,000 |
| NIDCD Clinical Research Center Grant (P50) Apply for PAR 13 277 Funding Number: PAR 13 277 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| USAID/Uganda Advocacy for Better Better Health Apply for RFA 617 13 000006 Funding Number: RFA 617 13 000006 Agency: Uganda USAID Kampala Category: Health Funding Amount: $20,000,000 |
| Limited Competition NIMHD Research Centers in Minority Institutions Infrastructure for Clinical and Translational Research (RCTR) U54 Apply for PAR 13 279 Funding Number: PAR 13 279 Agency: National Institutes of Health Category: Health Funding Amount: $3,100,000 |
| Clinical Trials in Organ Transplantation (CTOT) (U01) Apply for RFA AI 13 006 Funding Number: RFA AI 13 006 Agency: National Institutes of Health Category: Health Funding Amount: $1,750,000 |
| Support of NIGMS Program Project Grants (P01) Apply for PAR 13 280 Funding Number: PAR 13 280 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIMHD Social, Behavioral, Health Services, and Policy Research on Minority Health and Health Disparities (R01) Apply for RFA MD 13 006 Funding Number: RFA MD 13 006 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NINDS Phase III Investigator Initiated Efficacy Clinical Trials (U01) Apply for PAR 13 278 Funding Number: PAR 13 278 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Money Follows the Person Rebalancing Demonstration Grant Tribal Initiative Apply for CMS 1LI 14 001 Funding Number: CMS 1LI 14 001 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $1,000,000 |
| NINDS Exploratory Clinical Trials (R01) Apply for PAR 13 281 Funding Number: PAR 13 281 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Audacious Goals Initiative in Vision Research High Priority Research Area Molecular Therapies for Eye Disease (R01) Apply for PA 13 283 Funding Number: PA 13 283 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing Newborn, Child and Reproductive Health (ANCRE) Apply for USAID BENIN 680 13 00000 RFA Funding Number: USAID BENIN 680 13 00000 RFA Agency: Benin USAID Cotonou Category: Health Funding Amount: $10,000,000 |
| NIMHD Basic and Applied Biomedical Research on Minority Health and Health Disparities (R01) Apply for RFA MD 13 008 Funding Number: RFA MD 13 008 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Veterans to Nurses and Physician Assistants Workforce Program Apply for HRSA 13 275 Funding Number: HRSA 13 275 Agency: Health Resources and Services Administration Category: Health Funding Amount: $370,000 |
| IHS National HIV Program Apply for HHS 2013 IHS OCPS HIV 0001 Funding Number: HHS 2013 IHS OCPS HIV 0001 Agency: Indian Health Service Category: Health Funding Amount: $90,000 |
| Limited Competition International Cooperative Biodiversity Groups (U19) Apply for RFA TW 13 001 Funding Number: RFA TW 13 001 Agency: National Institutes of Health Category: Health Funding Amount: $700,000 |
| Network and Infrastructure Support for Development of Interdisciplinary Aging Research (R24) Apply for PAR 13 287 Funding Number: PAR 13 287 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Transformative Research Awards (R01) Apply for RFA RM 13 008 Funding Number: RFA RM 13 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Impact of Japanese Encephalitis Vaccination in Cambodia Apply for RFA CK 14 001 Funding Number: RFA CK 14 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $150,000 |
| Institutional Research and Academic Career Development Awards (IRACDA) (K12) Apply for PAR 13 290 Funding Number: PAR 13 290 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 14 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.